Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 1997

View Archived Issues

Genzyme Tissue Repair: Q3 1997 highlights

Genzyme Transgenics: Q3 1997 highlights

Celtrix: Q2 1997 highlights

Penederm: Q3 and nine-month 1997 highlights

Anika: Q3 1997 highlights

ImmuCell: Q3 1997 highlights

Laminin-like peptides available for licensing from NIH

New chemical candidate for treating cocaine addiction

Oxazolidinone antibacterial agents prepared at P&U

Merck KGaA reports two new series of ET antagonists

Samjin develops nucleosides for HIV

Vasopressin V1a receptor antagonists claimed for obsessive-compulsive disorder

New orally active thrombin inhibitors from Merck & Co.

nAChR ligands prepared at Astra

Clinical data reported for Actiq

Phase II results promising for E-047/1 following CABG

Effect of AMPA antagonist GYKI-52466 on oxygen balance in ischemic cortex

Clevidipine lowers MAC of anesthetic in animal study

Promising interim safety and efficacy data reported for Gd-Tex

Pharmacokinetics of anti-CD11b MAb in patients undergoing aneurysm repair

Initial results show Ethyol effective in reducing radiation-induced xerostomia

Human safety, immunogenicity and pharmacokinetics reported for h5G1.1-scFV

U.K. launch for Malarone, a potent new antimalarial combination

Genzyme General and Acadia enter drug discovery collaboration

Grant supports p53 gene research at The Wistar Institute

FibroGen granted license to Zeneca antifibrotic compounds

Inhibition of human pancreatic cancer invasion and metastasis by serine protease inhibitor

Pamidronate for preventing glucocorticoid-induced osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...